Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefan Walzer

Showing results (11-20 of 46) with videos related to

Pageof 5
Sort By:
Frontiers in Oncology|August 26, 2022
Nutritional support during the hospital stay is cost-effective for preventing adverse outcomes in patients with cancerPhilipp Schuetz, Suela Sulo, Stefan Walzer, et al.
Lung Cancer (Amsterdam, Netherlands)|August 24, 2010
Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and GermanyHelge G Bischoff, David F Heigener, Stefan Walzer, et al.
Clinicoeconomics and Outcomes Research : CEOR|June 11, 2016
Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin's lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic surveyClemente Ponzetti, Monica Canciani, Massimo Farina, et al.
Journal of Wound Care|March 7, 2018
A cost-effectiveness analysis of a hydration response technology dressing in the treatment of venous leg ulcers in the UKStefan Walzer, Daniel Dröschel, Lutz Vollmer, et al.
Pflege|September 3, 2025
[Sensor systems for the care of people with wandering behavior in hospital: A qualitative study on subjective experiences]Luisa Häfner, Stefan Walzer, Nicola Merz, et al.
Clinicoeconomics and Outcomes Research : CEOR|September 13, 2012
Cost comparison of second-line treatment options for late stage non-small-cell lung cancer: cost analysis for ItalyBjoern Schwander, Simona Ravera, Giovanni Giuliani, et al.
Oncology and Therapy|September 4, 2021
A Cost Impact Analysis of clonoSEQ<sup>®</sup> as a Valid and CE-Certified Minimal Residual Disease (MRD) Diagnostic Compared to No MRD Testing in Multiple Myeloma in GermanyStefan Walzer, Sebastian Krenberger, Lutz Vollmer, et al.
Journal of Medical Internet Research|July 31, 2025
Factors Influencing the Implementation and Adoption of Digital Nursing Technologies: Systematic Umbrella ReviewStefan Walzer, Christoph Armbruster, Sonja Mahler, et al.
BMC Nursing|December 7, 2023
Noise exposure among staff in intensive care units and the effects of unit-based noise management: a monocentric prospective longitudinal studyChristoph Armbruster, Stefan Walzer, Sandra Witek, et al.
Clinicoeconomics and Outcomes Research : CEOR|October 17, 2012
Societal savings in patients with advanced non-squamous non-small-cell lung cancer receiving bevacizumab-based versus non-bevacizumab-based treatments in France, Germany, Italy, and SpainJohanna Lister, Sanja Stanisic, Klaus Kaier, et al.
Pageof 5

Showing results (11-20 of 46) with videos related to

Sort By:
Pageof 5
Frontiers in Oncology|August 26, 2022
Nutritional support during the hospital stay is cost-effective for preventing adverse outcomes in patients with cancerPhilipp Schuetz, Suela Sulo, Stefan Walzer, et al.
Lung Cancer (Amsterdam, Netherlands)|August 24, 2010
Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and GermanyHelge G Bischoff, David F Heigener, Stefan Walzer, et al.
Clinicoeconomics and Outcomes Research : CEOR|June 11, 2016
Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin's lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic surveyClemente Ponzetti, Monica Canciani, Massimo Farina, et al.
Journal of Wound Care|March 7, 2018
A cost-effectiveness analysis of a hydration response technology dressing in the treatment of venous leg ulcers in the UKStefan Walzer, Daniel Dröschel, Lutz Vollmer, et al.
Pflege|September 3, 2025
[Sensor systems for the care of people with wandering behavior in hospital: A qualitative study on subjective experiences]Luisa Häfner, Stefan Walzer, Nicola Merz, et al.
Clinicoeconomics and Outcomes Research : CEOR|September 13, 2012
Cost comparison of second-line treatment options for late stage non-small-cell lung cancer: cost analysis for ItalyBjoern Schwander, Simona Ravera, Giovanni Giuliani, et al.
Oncology and Therapy|September 4, 2021
A Cost Impact Analysis of clonoSEQ<sup>®</sup> as a Valid and CE-Certified Minimal Residual Disease (MRD) Diagnostic Compared to No MRD Testing in Multiple Myeloma in GermanyStefan Walzer, Sebastian Krenberger, Lutz Vollmer, et al.
Journal of Medical Internet Research|July 31, 2025
Factors Influencing the Implementation and Adoption of Digital Nursing Technologies: Systematic Umbrella ReviewStefan Walzer, Christoph Armbruster, Sonja Mahler, et al.
BMC Nursing|December 7, 2023
Noise exposure among staff in intensive care units and the effects of unit-based noise management: a monocentric prospective longitudinal studyChristoph Armbruster, Stefan Walzer, Sandra Witek, et al.
Clinicoeconomics and Outcomes Research : CEOR|October 17, 2012
Societal savings in patients with advanced non-squamous non-small-cell lung cancer receiving bevacizumab-based versus non-bevacizumab-based treatments in France, Germany, Italy, and SpainJohanna Lister, Sanja Stanisic, Klaus Kaier, et al.
Pageof 5